Why Medpace Holdings, Inc.’s (MEDP) Stock Is Up 7.91%
As of Thursday, October 23, Medpace Holdings, Inc.’s MEDP share price has surged by 7.91%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Medpace Holdings, Inc. (MEDP)
Medpace Holdings, Inc. MEDP
$608.27
17.97
3.04%
August 19, 2026 4:00:00 PM
EST
Volume: 169,049
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Commentary & Analysis
What You Need to Know About Medpace Holdings, Inc.'s Q4 Earnings
Medpace Holdings, Inc.'s fiscal Q4 earnings report was released on Wednesday, October 22. Let's dive in to see if (MEDP) missed or beat analyst's expectations.Jenna Brashear
Why Medpace Holdings, Inc.’s (MEDP) Stock Is Down 5.37%
As of Friday, July 25, Medpace Holdings, Inc.’s MEDP share price has dipped by 5.37%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Medpace Holdings, Inc.’s (MEDP) Stock Is Down 6.64%
As of Wednesday, July 23, Medpace Holdings, Inc.’s MEDP share price has dipped by 6.64%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Medpace Holdings, Inc.’s (MEDP) Stock Is Up 55.08%
As of Tuesday, July 22, Medpace Holdings, Inc.’s MEDP share price has surged by 55.08%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | MEDP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $17,107.6 | $3,076.5 | 84% |
|
| Shares Out (Mil) | 28.6 | 96.5 | 36% |
|
| Institutional Ownership | 80.9% | 90.0% | 50% |
|
| Float (Mil) | 22.4 | 71.5 | 31% |
|
| Beta | 1.15 | 1.22 | 69% |
|
| Avg Daily Volume (000s) | 192 | 710 | 43% |
|
| Price Change (52-week) |
32.6% | 89.4% | 71% |
|
| Growth | MEDP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 22.3% | 7.8% | 84% |
|
| Net Income (5yr) | 25.4% | (13.7%) | 80% |
|
| EPS (5yr) | 31.8% | 0.7% | 83 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (28.2%) | (15.0%) | 21% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 10 | 10 | |
| Current EPS | $4.438 | $17.705 | $19.310 | |
| Month Ago EPS | $4.303 | $17.167 | $18.749 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | $4.284 | $17.105 | $18.562 | |
| Year/Year Chg | 4.4% | 15.9% | 41.8% | |
| Financials | MEDP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,782 | $800 | 65% |
|
| Net Income (TTM) (Mil) | $492 | ($31) | 78% |
|
| EPS (TTM) | $17.395 | ($0.300) | 97% |
|
| Operating Cash Flow (TTM) (Mil) | $753 | $47 | 77% |
|
| Net Cash Flow (TTM) (Mil) | $456 | $5 | 90% |
|
| Long-Term Debt (Q1) (Mil) | $120 | $270 | 46% |
|
| Enterprise Value (Q1) (Mil) | $16,427 | $3,795 | 81% |
|
| Valuation | MEDP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 39.44 | 3.68 | 98% |
|
| P/E | 35.9 | 39.8 | 76% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 1.1 | 5.5 | 50% |
|
| Ratios | MEDP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 72.3% | 47.7% | 83% |
|
| Net Margin | 17.7% | (3.2%) | 76% |
|
| ROA | 27.1% | (4.3%) | 98% |
|
| ROE | 162.2% | (7.9%) | 98% |
|
| Liabilities to Assets | 78.9% | 42.0% | 74% |
|
| F-Score | 8 | 5 | 93% |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
O'Neil's CAN SLIM No Float Screen
Factors: Momentum, Growth
An approach that combines both fundamental and technical factors to seek out companies with strong earnings and price momentum.
| Performance Since Inception: | 12.9% |
| +/- S&P 500: | +5.4 |
Passing Stocks
| DXP Enterprises, Inc. | DXPE |
| Interactive Brokers Group, Inc. | IBKR |
| Medpace Holdings, Inc. | MEDP |
| Navigator Holdings Ltd. | NVGS |
